CGP-37849
 | |
| Clinical data | |
|---|---|
| Other names | CGP-37849, CGP-40116 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C6H12NO5P |
| Molar mass | 209.138 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
CGP-37849 is a competitive antagonist at the NMDA receptor.[1] It is a potent, orally active anticonvulsant in animal models,[2] and was researched for the treatment of epilepsy.[3] It also has neuroprotective activity[4] and shows antidepressant[5][6] and anxiolytic effects.[7][8]
References
[edit]- ^ Fagg GE, Olpe HR, Pozza MF, Baud J, Steinmann M, Schmutz M, et al. (April 1990). "CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity". British Journal of Pharmacology. 99 (4): 791–7. doi:10.1111/j.1476-5381.1990.tb13008.x. PMC 1917531. PMID 1972895.
- ^ Schmutz M, Portet C, Jeker A, Klebs K, Vassout A, Allgeier H, et al. (July 1990). "The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents". Naunyn-Schmiedeberg's Archives of Pharmacology. 342 (1): 61–6. doi:10.1007/bf00178973. PMID 1976233. S2CID 25531153.
- ^ Fujikawa DG, Daniels AH, Kim JS (March 1994). "The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage". Epilepsy Research. 17 (3): 207–19. doi:10.1016/0920-1211(94)90051-5. PMID 7912191. S2CID 13656613.
- ^ Gutnikov SA, Gaffan D (June 1996). "Systemic NMDA receptor antagonist CGP-40116 does not impair memory acquisition but protects against NMDA neurotoxicity in rhesus monkeys". The Journal of Neuroscience. 16 (12): 4041–5. doi:10.1523/JNEUROSCI.16-12-04041.1996. PMC 6578604. PMID 8656297.
- ^ Maj J, Klimek V, Gołembiowska K, Rogóz Z, Skuza G (1993). "Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity". Polish Journal of Pharmacology. 45 (5–6): 455–66. PMID 7912134.
- ^ Papp M, Moryl E (September 1994). "Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression". European Journal of Pharmacology. 263 (1–2): 1–7. doi:10.1016/0014-2999(94)90516-9. PMID 7821340.
- ^ Jessa M, Nazar M, Bidzinski A, Plaznik A (March 1996). "The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety". European Neuropsychopharmacology. 6 (1): 55–61. doi:10.1016/0924-977x(95)00068-z. PMID 8866939. S2CID 45953054.
- ^ Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E (July 2000). "The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats". Neuropharmacology. 39 (10): 1858–64. doi:10.1016/s0028-3908(00)00023-x. PMID 10884566. S2CID 33660694.